Study to Evaluate the Safety and Immunogenicity of an HIV-1 Vaccine Regimen of Adjuvanted UVAX-1107 Followed by Adjuvanted UVAX-1107 or Adjuvanted UVAX-1197 in Healthy Subjects Aged 25-55 Years.
Early Phase 1
Completed
- Conditions
- HIV InfectionsAIDS/HIV - RelatedDisease Associated With AIDSVaccine-Preventable Diseases
- Interventions
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Uvax Bio LLC
- Target Recruit Count
- 34
- Registration Number
- NCT06541093
- Locations
- 🇦🇺
Nucleus Network Melbourne, Melbourne, Victoria, Australia
© Copyright 2025. All Rights Reserved by MedPath